BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 33631016)

  • 21. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
    Infante JR; Cohen RB; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; LoRusso PM
    Invest New Drugs; 2017 Oct; 35(5):576-588. PubMed ID: 28424891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving outcomes for neurofibromatosis 1-associated brain tumors.
    Brossier NM; Gutmann DH
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):415-23. PubMed ID: 25652347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
    Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
    Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes.
    Green K; Panagopoulou P; D'Arco F; O'Hare P; Bowman R; Walters B; Dahl C; Jorgensen M; Patel P; Slater O; Ahmed R; Bailey S; Carceller F; Collins R; Corley E; English M; Howells L; Kamal A; Kilday JJ; Lowis S; Lumb B; Pace E; Picton S; Pizer B; Shafiq A; Uzunova L; Wayman H; Wilson S; Hargrave D; Opocher E
    Neuro Oncol; 2023 Apr; 25(4):774-785. PubMed ID: 36239316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visual acuity of children treated with chemotherapy for optic pathway gliomas.
    Kalin-Hajdu E; DĂ©carie JC; Marzouki M; Carret AS; Ospina LH
    Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Visual improvement despite radiologically stable disease after treatment with carboplatin in children with progressive low-grade optic/thalamic gliomas.
    Mitchell AE; Elder JE; Mackey DA; Waters KD; Ashley DM
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):572-7. PubMed ID: 11902299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
    Fouladi M; Nicholson HS; Zhou T; Laningham F; Helton KJ; Holmes E; Cohen K; Speights RA; Wright J; Pollack IF;
    Cancer; 2007 Dec; 110(11):2535-41. PubMed ID: 17932894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.
    Falzon K; Drimtzias E; Picton S; Simmons I
    Br J Ophthalmol; 2018 Oct; 102(10):1367-1371. PubMed ID: 29343527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
    Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
    J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.
    Fangusaro JR; Onar-Thomas A; Poussaint TY; Wu S; Ligon AH; Lindeman NI; Banerjee A; Packer R; Kilburn LB; Pollack IF; Qaddoumi IA; Fisher PG; Dhall G; Baxter PA; Kreissman SG; Doyle LA; Smith MA; Fouladi M; Dunkel IJ
    Neuro Oncol; 2022 Aug; 24(8):1404. PubMed ID: 35307742
    [No Abstract]   [Full Text] [Related]  

  • 31. Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.
    Cappellano AM; Petrilli AS; da Silva NS; Silva FA; Paiva PM; Cavalheiro S; Bouffet E
    J Neurooncol; 2015 Jan; 121(2):405-12. PubMed ID: 25366366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1.
    Wan MJ; Ullrich NJ; Manley PE; Kieran MW; Goumnerova LC; Heidary G
    J Neurooncol; 2016 Aug; 129(1):173-8. PubMed ID: 27311725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.
    Ater JL; Xia C; Mazewski CM; Booth TN; Freyer DR; Packer RJ; Sposto R; Vezina G; Pollack IF
    Cancer; 2016 Jun; 122(12):1928-36. PubMed ID: 27061921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optic Pathway Gliomas in Neurofibromatosis Type 1.
    Campen CJ; Gutmann DH
    J Child Neurol; 2018 Jan; 33(1):73-81. PubMed ID: 29246098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early radiotherapy preserves vision in sporadic optic pathway glioma.
    Hanania AN; Paulino AC; Ludmir EB; Shah VS; Su JM; McGovern SL; Baxter PA; McAleer MF; Grosshans DR; Okcu MF; Chintagumpala MM
    Cancer; 2021 Jul; 127(13):2358-2367. PubMed ID: 33739455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab.
    Theeler BJ; Ellezam B; Yust-Katz S; Slopis JM; Loghin ME; de Groot JF
    J Neurol; 2014 Aug; 261(8):1559-64. PubMed ID: 24859329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
    Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
    J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurofibromatosis type 1 and sporadic optic gliomas.
    Singhal S; Birch JM; Kerr B; Lashford L; Evans DG
    Arch Dis Child; 2002 Jul; 87(1):65-70. PubMed ID: 12089128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.
    Suenobu S; Terashima K; Akiyama M; Oguri T; Watanabe A; Sugeno M; Higashimori M; So K; Nishida Y
    Neurooncol Adv; 2023; 5(1):vdad054. PubMed ID: 37287695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.
    Tang P; Roldan G; Brasher PM; Fulton D; Roa W; Murtha A; Cairncross JG; Forsyth PA
    J Neurooncol; 2006 Jul; 78(3):311-6. PubMed ID: 16710748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.